Tissue Regenix (LON:TRX) has increased Medicare coverage for skin graft product DermaPure to almost two-thirds of the US with First Coast Service Options' approval for the product.
Medicare is the US’s health scheme for the elderly and approval from its administrators is crucial for a product to be prescribed as an outpatient treatment by hospitals and doctors’ surgeries.
First Coast’s jurisdiction includes Florida, Puerto Rico and the US Virgin Islands and increases the number of potential patients for Dermapure by 2.5mln.
DermaPure is now available across 31 States, the US Virgin Islands and Puerto Rico, which account for 65% of the 37mln beneficiaries enrolled under the Medicare programme.
Antony Odell, Tissue Regenix’s chief executive, said: “Commercial interest in DermaPure continues to grow and I look forward to announcing further LCD coverage approvals and expanding commercial payer coverage in due course."